Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation–Positive Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation–Positive Non–Small Cell Lung Cancer

Published:2020-07-09 Issue:7 Volume:6 Page:e201250
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Miyamoto Shingo¹,Azuma Koichi²,Ishii Hidenobu²,Bessho Akihiro³,Hosokawa Shinobu³,Fukamatsu Nobuaki³,Kunitoh Hideo¹,Ishii Mari⁴,Tanaka Hiroshi⁵,Aono Hiromi⁶,Nakahara Yoshiro⁷,Kusaka Kei⁸,Hosomi Yukio⁹,Kikuchi Norihiro¹⁰,Mori Yoshiaki¹¹,Itani Hidetoshi¹²,Hamada Akinobu¹³,Yamada Kazuhiko²,Okamoto Hiroaki⁴

Affiliation:

1. Department of Medical Oncology, Japanese Red Cross Medical Center, Tokyo, Japan

2. Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan

3. Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama, Japan

4. Department of Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizen’s Hospital, Yokohama, Japan

5. Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan

6. Respiratory Medicine, Mitsui Memorial Hospital, Tokyo, Japan

7. Department of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara, Japan

8. The Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan

9. Department of Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan

10. Department of Respiratory Medicine, Kasumigaura Medical Center, Tsuchiura, Japan

11. Department of Respiratory Medicine, Iwate Prefectural Central Hospital, Morioka, Japan

12. Department of Respiratory Medicine, Japanese Red Cross Ise Hospital, Ise, Japan

13. Division of Molecular Pharmacology, National Cancer Center Research Institute, Tokyo, Japan

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2765756/jamaoncology_miyamoto_2020_oi_200017.pdf

Reference21 articles.

1. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR.;Maemondo;N Engl J Med,2010

2. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.;Sequist;J Clin Oncol,2013

3. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer.;Soria;N Engl J Med,2018

4. First-line gefitinib for patients with advanced non–small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.;Inoue;J Clin Oncol,2009

5. First-line gefitinib in patients aged 75 or older with advanced non–small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.;Maemondo;J Thorac Oncol,2012

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High-cost treatments for advanced lung cancer in Japan (Lung Cancer Study Group of the Japan Clinical Oncology Group);Japanese Journal of Clinical Oncology;2024-08-19

2. Multi‐synergistic chemotherapeutic drug assemblies to activate colorectal cancer immunotherapy by modulating the multilevel immunosuppressive characteristics;Aggregate;2024-06-26

3. Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non‐small‐Cell Lung Cancer in Patients Aged 75 Years and Older;Clinical Pharmacology & Therapeutics;2024-06-17

4. Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Non-Small Cell Lung Cancer Patients with Poor Performance Status and Epidermal Growth Factor Receptor Mutations: Findings from the Japanese Lung Cancer Registry Database;Clinical Lung Cancer;2024-06

5. Multi-institutional study of osimertinib dose-optimization in non-small cell lung cancer patients with EGFR activating mutation aged 70 years or older (‘MONEY’ trial);Japanese Journal of Clinical Oncology;2024-03-22